Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose Oral vs IV Rifampicin in TB Meningitis
NCT01802502Phase 2Completed
- Sponsor
- Universitas Padjadjaran
- Start
- Jun 2013
- Primary completion
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rifampicin in tuberculous meningitis (TBM) (3 arms), sponsored by Universitas Padjadjaran. Primary endpoint: Pharmacokinetic profile of rifampicin at Day 14. Started Jun 2013; status: completed.
02
Drugs
rifampicin
03
Conditions
tuberculous meningitis (TBM)
Beyond the preview
Go deeper on NCT01802502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01802502.